Ray Therapeutics raised an upsized, oversubscribed $125 million Series B to advance its vision restoration treatments.
- Amount
- $125M
- Stage
- Series B
- Announced
- 21 April 2026
- Lead
- Janus Henderson Investors
- Other investors
- Adage Capital Management, Franklin Templeton, Invus, Marshall Wace, 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings A/S, Platanus
- Use of funds
- Late-stage clinical development and commercial readiness for RTx-015, and clinical studies for RTx-021.
- Checked
- Amount and date checked against the press source